JP2023538449A - ウイルス阻害剤 - Google Patents

ウイルス阻害剤 Download PDF

Info

Publication number
JP2023538449A
JP2023538449A JP2023513169A JP2023513169A JP2023538449A JP 2023538449 A JP2023538449 A JP 2023538449A JP 2023513169 A JP2023513169 A JP 2023513169A JP 2023513169 A JP2023513169 A JP 2023513169A JP 2023538449 A JP2023538449 A JP 2023538449A
Authority
JP
Japan
Prior art keywords
mol
group
substituted
carbohydrate compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538449A5 (https=
Inventor
ウチェグブ，イジェオマ
シャッツライン，アンドレアス
パイロク，クシシュトフ
ミレウスカ，アレクサンドラ
デュラン，エミリア バレット
Original Assignee
ナノメリクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2013221.3A external-priority patent/GB202013221D0/en
Priority claimed from GBGB2019097.1A external-priority patent/GB202019097D0/en
Priority claimed from GBGB2105404.4A external-priority patent/GB202105404D0/en
Application filed by ナノメリクス リミテッド filed Critical ナノメリクス リミテッド
Publication of JP2023538449A publication Critical patent/JP2023538449A/ja
Publication of JP2023538449A5 publication Critical patent/JP2023538449A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023513169A 2020-08-24 2021-08-24 ウイルス阻害剤 Pending JP2023538449A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2013221.3 2020-08-24
GBGB2013221.3A GB202013221D0 (en) 2020-08-24 2020-08-24 Viral inhibitors
GB2019097.1 2020-12-03
GBGB2019097.1A GB202019097D0 (en) 2020-12-03 2020-12-03 Viral inhibitors
GBGB2105404.4A GB202105404D0 (en) 2021-04-15 2021-04-15 Viral inhibitors
GB2105404.4 2021-04-15
PCT/GB2021/052199 WO2022043678A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Publications (2)

Publication Number Publication Date
JP2023538449A true JP2023538449A (ja) 2023-09-07
JP2023538449A5 JP2023538449A5 (https=) 2024-08-14

Family

ID=77655566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513169A Pending JP2023538449A (ja) 2020-08-24 2021-08-24 ウイルス阻害剤

Country Status (8)

Country Link
US (1) US20230330132A1 (https=)
EP (1) EP4199937A1 (https=)
JP (1) JP2023538449A (https=)
CN (1) CN116367843A (https=)
AU (1) AU2021333748A1 (https=)
CA (1) CA3192515A1 (https=)
MX (1) MX2023002109A (https=)
WO (1) WO2022043678A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503933A (ja) * 2002-09-20 2006-02-02 ザ・ユニバーシティ・オブ・ストラスクライド 親水性基および疎水性基で置換された可溶化多糖類
JP2007513959A (ja) * 2003-12-10 2007-05-31 エスディー ファーマシューティカルズ インコーポレイティッド 抗ウイルス性薬学的組成物
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
JP2015520755A (ja) * 2012-05-18 2015-07-23 ウニヴェルスィテット ヤギエルロンスキ コロナウイルスに起因する感染の治療及び予防におけるキトサンポリマーの使用
WO2020039463A1 (en) * 2018-08-23 2020-02-27 Haskoli Islands Chitosan derivatives and methods for preparing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503933A (ja) * 2002-09-20 2006-02-02 ザ・ユニバーシティ・オブ・ストラスクライド 親水性基および疎水性基で置換された可溶化多糖類
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
JP2007513959A (ja) * 2003-12-10 2007-05-31 エスディー ファーマシューティカルズ インコーポレイティッド 抗ウイルス性薬学的組成物
JP2015520755A (ja) * 2012-05-18 2015-07-23 ウニヴェルスィテット ヤギエルロンスキ コロナウイルスに起因する感染の治療及び予防におけるキトサンポリマーの使用
WO2020039463A1 (en) * 2018-08-23 2020-02-27 Haskoli Islands Chitosan derivatives and methods for preparing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MILEWSKA, A. ET AL.: "Novel polymeric inhibitors of HCoV-NL63", ANTIVIRAL RESEARCH, vol. 97, no. 2, JPN6025040698, 2013, pages 112 - 121, ISSN: 0005703093 *
最新 医学大事典, vol. 第２版, JPN6025040699, 2001, pages 798 - 799, ISSN: 0005703092 *

Also Published As

Publication number Publication date
CN116367843A (zh) 2023-06-30
CA3192515A1 (en) 2022-03-03
MX2023002109A (es) 2023-07-13
WO2022043678A1 (en) 2022-03-03
EP4199937A1 (en) 2023-06-28
US20230330132A1 (en) 2023-10-19
AU2021333748A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Yasamineh et al. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19
Pramanik et al. Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases
Pyrć et al. SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray
CA2871778C (en) Pharmaceutical nanoparticles showing improved mucosal transport
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
DK3193835T3 (en) Liquid inhalation formulation comprising RPL554
JP2010537997A (ja) 二機能性ポリマーに結合させたインフルエンザウイルス阻害剤
US12239629B2 (en) Methods for the prophylaxis and treatment of COVID and COVID-19
JP2010512307A (ja) 抗ウイルス組成物及び使用方法
KR20210056379A (ko) 살바이러스 나노입자 및 인플루엔자 바이러스에 대한 이의 용도
JP2019524724A (ja) テコビリマットの経口用医薬組成物及びその調製法
JP2023538449A (ja) ウイルス阻害剤
Freeman et al. An aerosol nanocomposite microparticle formulation using rifampicin-cyclodextrin inclusion complexes for the treatment of pulmonary diseases
JP7577652B2 (ja) インフルエンザウイルス複製の阻害剤の組み合わせ
US12539312B2 (en) Use of materials made of cross-linked β-cyclodextrins for the treatment of tuberculosis
JP2022515570A (ja) インフルエンザ及び合併症リスク因子を有する対象における置換多環式ピリドン誘導体及びそのプロドラッグを用いたインフルエンザの処置
CN116744934A (zh) 用于治疗病毒性呼吸疾病的吸入性他汀类药物
TW202038908A (zh) 佈雷那蘭之口服配製物
US20240041805A1 (en) Pharmaceutical compositions of niclosamide and a protein
WO2021236626A1 (en) Mucoretentive antiviral technologies
WO2022020766A1 (en) Materials and methods for the prevention and treatment of viral respiratory diseases
Heida et al. Inhibition of influenza virus infection in mice by pulmonary administration of a spray dried antiviral drug
EP4319784B1 (en) Pharmaceutical composition for use in a treatment of virus-induced disease
US20240350511A1 (en) Treatment of covid-19
TWI830882B (zh) 使用經取代之多環吡啶酮衍生物及其前藥在具有流感及併發症危險因子的個體中治療流感

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331